Evaluation of in vivo anti-inflammatory activity of Ariflex tablet in comparison with diclofenac and aceclofenac tablet in carrageenan induced rat paw edema model

Background: Osteoarthritis is a major cause of pain and locomotor disability worldwide. Though various pharmacological, mechanical and surgical interventions are used, there is no known cure for OA. The present study was conducted to evaluate anti-inflammatory activity of Ariflex tablet (conceptualized and developed by Ari Healthcare Pvt. Ltd.) in comparison with diclofenac and aceclofenac tablet in carrageenan induced rat paw edema model.Methods: Wistar rats of either sex weighing 150-180 g were taken and divided into 4 groups with 6 animals in each group i.e. group 1 (control group), group 2 (diclofenac tablet), group 3 (aceclofenac tablet) and group 4 (ariflex tablet). The study drugs were orally administered with feeding needle, 30 minutes prior to carrageenan injection. After 30 min 1% w/v of 0.05 ml carrageenan was injected subcutaneously in the rat paw. The paw was marked with ink at the level of lateral malleolus and immersed in mercury up to lateral malleolus mark. The paw volume was measured plethysmographically after injection at 30 minutes, 1 hour, 2 hour, 3 hour, 4 hour and eventually at 5 hour.Results: All the test formulations possess statistically significant (p<0.05) anti-inflammatory activity as compared to control group. The maximum percentage inhibition for Ariflex tablet was 96.97% at the end of 5 hours. When compared to control group, statistically significant reduction of paw edema was observed. The anti-inflammatory activity of Ariflex tablet from 2 hours onwards is comparable to that of diclofenac tablet and aceclofenac tablet.Conclusions: Ariflex tablet possesses significant anti-inflammatory activity

EVALUATION OF ANTI-INFLAMMATORY (IN VIVO) ACTIVITY OF ARIFLEX LINIMENT IN COMPARISON WITH DICLOFENAC GEL IN CARRAGEENAN INDUCED RAT PAW EDEMA MODEL

Objective: The present study was conducted to evaluate anti-inflammatory activity of Ariflex liniment (conceptualized and developed by Ari Healthcare Pvt. Ltd) in comparison with Diclofenac gel in carrageenan induced rat paw edema model. Methods: Wistar rats of either sex weighing 150-180 g were taken and divided into 3 groups with 6 animals in each group i.e. Group 1 (Controlled Group), Group 2 (Diclofenac gel) and Group 3 (Ariflex liniment). The study drugs were topically applied 30 min prior to carrageenan injection. After 30 min 1% w/v of 0.05 ml carrageenan was injected subcutaneously in the paw. The paw was marked with ink at the level of lateral malleolus and immersed in mercury up to the lateral malleolus mark. The paw volume was measured plethysmographically, immediately after injection i.e. on 0 min, and then on 30 min,1h, 2h,3h, 4h and 5hr after injection. Results: Diclofenac gel sodium treated group showed significant inhibition (p&lt;0.01) of paw edema at 30 min, 1, 2, 3, 4 and 5th hrs as compared to control group. Ariflex Liniment showed significant inhibition (p&lt;0.05) of paw edema at 30 min, 1, 2, 3, and 4th hrs as compared to the control group. Group treated with Ariflex Liniment did not show any significant decrease in paw edema volume at 5th hrs when compared to the control group. Conclusion: Ariflex Liniment possesses anti-inflammatory activity

Evaluation of analgesic (in vivo) activity of Ariflex liniment in comparison with diclofenac gel by acetic acid induced writhing model

Background: Adverse effects of available medications for osteoarthritis (OA) and rheumatoid arthritis (RA) necessitate development of safer and effective alternative medicinal substitutes. The present study was conducted to evaluate analgesic activity of Ariflex liniment (conceptualized and developed by Ari Healthcare Pvt. Ltd.) in comparison with diclofenac gel by using acetic acid induced writhing model.Methods: Albino mice of either sex weighing 20-25 g were taken and divided into 3 groups with 5 animals in each group, i.e., group 1 (control group), group 2 (diclofenac gel) and group 3 (Ariflex liniment). After 1 hour of topical application of study drugs writhing was induced in mice using intra-peritonial injection of 1% acetic acid in volume of 0.1 ml/10 g body weight. Then the writhing episodes were recorded for 30 minutes and results were noted.Results: In the control group, the total number of  writhes were 260±29.73 (mean±S. E. M.). The total number of writhes was 12.17±11.81 (mean ± S. E. M.) in diclofenac group. In Ariflex liniment group, not a single animal felt pain, hence there were no writhes recorded. When compared to control group, the difference in number of writhes was statistically significant. The analgesic activity of Ariflex liniment was found to be superior to that of diclofenac gel used as standard drug.Conclusions: It can be concluded that Ariflex liniment possesses analgesic activity

EVALUATION OF ANALGESIC (IN VIVO) ACTIVITY OF ARIFLEX TABLET IN COMPARISON WITH DICLOFENAC AND ACECLOFENAC USING ACETIC ACID INDUCED WRITHING MODEL IN MICE

Objective: The present study was conducted to evaluate analgesic activity of Ariflex Tablet which is a polyherbal formulation conceptualized and developed by Ari Healthcare Private in comparison to Aceclofenac and Diclofenac Tablet. Methods: Albino mice of either sex weighing 20–25 g were taken and divided into four groups with six animals in each group. Group 1 (Controlled Group) animals were starved overnight. Group 2 animals were orally administered with Diclofenac Tablet as Standard drug. Group 3 animals were orally administered with Aceclofenac Tablet as Standard drug and Group 4 Animals were orally administered with Ariflex Tablet. The test and standard drugs were orally administered with feeding needle after 1 h of injecting 1% acetic acid intraperitoneally in volume of 0.1 ml/10 g body weight. Writhing episodes were recorded for 30 min by counting the stretching. Results: All the tested formulations possess analgesic activity in acetic acid induced writhing model. Aceclofenac possesses strong analgesic activity compared to other formulations tested. In Ariflex Tablet Group, the number of writhes was 120.6±41.4. If compared to control group, the number of writhes was significantly less suggesting analgesic activity of Ariflex Tablet. Analgesic activity of Ariflex Tablet was close to that of Diclofenac Sodium. Conclusion: It can be concluded that Ariflex Tablet possesses significant analgesic activity. Ariflex Tablet can be used in the management of Osteoarthritis, Rheumatoid arthritis, Gouty arthritis, Lumbago, Sciatica, and Spondylitis

Comparative efficacy of two polyherbal creams with framycetin sulfate on diabetic wound model in rats

Background: Diabetes mellitus is one of the metabolic disorders that impede normal steps of wound healing process. Worldwide, 15% of the 200 million diabetics suffer from diabetic wounds. Diabetic complications, such as foot ulcer, impose major public health burdens worldwide. Objective: The present study was carried out to evaluate comparative efficacy of polyherbal creams with framycetin sulfate cream on diabetic rats using incision and excision wound models. Materials and methods: Alloxan (120 mg/kg, intraperitoneal) induced diabetic rat models (incision and excision models) were used to evaluate wound healing effect of cream A, B, and framycetin sulfate. Cream A and B were applied for a period of 10 and 20 days for incision and excision wound models, respectively. Incision wound model was used to assess the effect on breaking strength. Wound contraction and epithelialization period were measured using excision wound model. The data were analyzed by one-way ANOVA followed by Bonferroni post-test. Results: Tensile strength of the animals treated with cream B (941.66 ± 15.36) was found to be significantly greater (P < 0.001) as compared to tensile strength of the animals treated with cream A (825 ± 22.36). Wound treated with cream B was found to heal significantly (P < 0.001) faster (day 17) as compared to wounds treated with framycetin sulfate (day 21). Conclusions: Cream B was found to be more effective wound healing agent than cream A and framycetin sulfate cream in treating diabetic wounds

An open label, prospective, clinical study on a polyherbal formulation in osteoarthritis of knee

Background: Currently, though pharmacological, mechanical, and surgical interventions are used, there is no known cure for osteoarthritis (OA). Objectives: The main aim of the study was to assess the efficacy and safety of "TLPL/AY/03/2008," a polyherbal formulation on knee joint pain assessed on visual analogue scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Materials and Methods: It was an open label, single center, prospective, clinical study conducted in 36 patients of OA Knee. Two capsules of ′TLPL/AY/03/2008′ were given to all patients twice daily orally after meals for 180 days. Results: Data describing quantitative measures are expressed as mean ± SD. Comparison of variables representing categorical data was performed using Chi-square test. The mean joint pain (as assessed on VAS) reduced significantly (59.85%; P < 0.05) and the mean WOMAC combined score, WOMAC pain sub-score, WOMAC stiffness sub-score, and WOMAC difficulty sub-score also reduced significantly at the end of the study. The mean time taken by the patients to walk 50 feet too, was reduced significantly (25.26%) at the end of the study. At the end of 4 months of the treatment, no patient needed paracetamol as rescue medicine to control pain. Most of the patients had shown good overall improvement assessed by the physician and by the patients. Majority of the patients showed excellent tolerability to the study drug. No significant change in most of the safety laboratory parameters was observed at the end of the study. Conclusion: The study provides good evidence in support of the efficacy and safety of the ′TLPL/AY/03/2008′ in OA of knee

An open-label, interventional, single-center, prospective clinical study to evaluate the efficacy and safety of “AHPL/AYTAB/1514” in patients suffering from halitosis

Objectives: The main objective of the study was to assess the efficacy and safety of AHPL/AYTAB/1514 tablet in patients suffering from halitosis. Methodology: Fifty four patients were recruited in the study. Patients were advised to take maximum two tablets or at least one tablet four times a day (depending on tolerability of the drug) orally for 60 days. Patients were called for follow-up on day 15, 30, 45, 60, and 75. Data describing quantitative measures were expressed as mean ± standard deviation comparison of variables representing categorical data were performed using Chi-square test, Student's t-test, or Wilcoxon Sign Rank test. Results: At the end of the treatment, significant reduction in halitosis, gingivitis index, and dental plaque index was observed. Even after stoppage of treatment for 15 days after 60 days of treatment, there was no relapse in halitosis. Few patients experienced sore throat, cough, and common cold during the study, which were resolved with the treatment of AHPL/AYTAB/1514 tablet. No significant change in vital parameters and most of the safety laboratory parameters were observed. No staining on tooth was observed in any patient. Almost all patients showed excellent improvement as per global evaluation done by the physician and patient. Almost all patients showed excellent tolerability to the study drug. Few patients showed mild AE, which were resolved without stoppage of study drug. Conclusion: The study provides good evidence in support of the efficacy and safety of the AHPL/AYTAB/1514 tablet in halitosis

International Journal of Pharma and Bio Sciences RESEARCH ARTICLE PHARMACOLOGY ACUTE AND 28-DAY REPEATED DOSE TOXICITY STUDIES WITH POLYHERBAL FORMULATION OF ISABGOL HUSK, SWARNAPATRI LEAF EXTRACT AND TRIPHALA FRUITS EXTRACT (TLPL/AY/01/2008)

The acute and sub-chronic 28-day repeated dose toxicity studies in rodents were performed to assess the safety of polyherbal formulation of Isabgol husk (Plantago ovate), Swarnapatri leaf extract (Cassia angustifolia) and Triphala fruits extract (Emblica officinalis, Terminalia chebula and Terminalia belerica) (TLPL/AY/01/2008). The studies were conducted according to current OECD toxicology guidelines for acute and repeated dose. No mortalities or evidence of adverse effects were observed following acute oral gavage administration up to 2000 mg/kg of TLPL/AY/01/2008 in Sprague dawley rats. The 28-day repeated dose study involving daily oral administration of 70, 175 and 350 mg/kg body weight of TLPL/AY/01/2008, with a post trial 14 day no treatment observation period at high dose level, resulted in no clinical signs and animal deaths. No toxicological significant differences were observed in any of the TLPL/AY/01/2008 treatment groups for body weights, feed consumption, physical appearance, neurological behaviour and urine analysis. Evaluation of haematology and clinical chemistry parameters revealed no toxicological and treatment related effects. No treatment related changes noted in absolute and relative organ weights. Macroscopic and microscopic evaluation of organs revealed no treatment related. Results of this study demonstrate that polyherbal formulation TLPL/AY/01/2008 is not acutely toxic at 2000 mg/kg of bod